Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Minerva Neurosciences faces FDA challenges with roluperidone in Q4

Minerva Neurosciences' Q4 2022 earnings call highlighted challenges with FDA interactions for roluperidone, alongside financial updates. Despite hurdles, the company expressed confidence in its data package and the potential of roluperidone to meet medical needs. Ongoing FDA dialogue remains critical for addressing regulatory concerns and advancing the schizophrenia treatment.

Minerva Neurosciences advances NDA filing for roluperidone, faces regulatory challenges

Minerva Neurosciences showcased progress in drug development and financial stability while facing challenges in regulatory processes and financial uncertainties. The company's strategic focus on unique drug profiles and milestone achievements presents opportunities for growth and market success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

Shares of Minerva Neurosciences NERV, -19.45% fell 20% in afternoon trading after it said a mid-stage trial for its experimental depression treatment did not meet its primary or secondary endpoints.

Minerva shares fall on failed depression drug trial

Testifying to the tough development pathway for central nervous disorder drugs, another biotech announced a failed study of its experimental drug to treat major depressive disorder, or MDD, and also said it's shelving the clinical program, sending shares sharply lower.

Minerva Neurosciences Shelves Depression Drug Study After Failed Mid-Stage Trial

Minerva's shares are crumbling today on the heels of a major clinical setback.

Why Minerva Neurosciences Stock Is Cratering Today

ACADIA Pharma

Karuna Therapeutics Inc

Neurocrine Biosciences

4 Biotech Neurology Stocks, As Biotechs March On

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q3 2019 Results - Earnings Call Transcript

Axsome Therapeutics

Two healthcare stocks, two plunging stock prices, and two unique scenarios heading into the end of 2019.

These 2 Neuroscience Stocks Have Tanked as Much as 33% Since September 1. Are They Buys?

A cyberattack resulted in a clinical trial delay. Really.

Here's Why Minerva Neurosciences Fell Over 28% Today

After Minerva Neurosciences Inc. (NASDAQ: NERV) announced that it was the victim of a cyberattack, its shares dropped sharply on Tuesday.

Are Biotechs the Next Target for Cyber Criminals?

Shares of Minerva Neurosciences Inc. NERV, -5.26% plummeted 28% to pace all premarket decliners Tuesday, after the biopharmaceutical company said a cyber-attack on an external contractor resulted in delays in patient recruitment for the phase 3 trial of its schizophrenia treatment, roluperidone.

Minerva's stock plunges to lead all premarket losers after cyber-attack delays enrollment in a phase 3 trial

Company to host conference call at 8:30 a.m. today (dial-in information below) Company to host conference call at 8:30 a.m. today (dial-in information below)

Minerva Neurosciences Announces Update for Three Clinical Trials

Minerva Neurosciences is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: Minerva Neurosciences

Minerva Neurosciences, Inc.'s (NERV) CEO Remy Luthringer on Q2 2019 Results - Earnings Call Transcript

In the latest Minerva Neurosciences news, NERV stock is skyrocketing as the company's insomnia treatment trial yielded positive results.
The post Minerva Neurosciences News: NERV Stock Up on Insomnia Treatment Trial appeared first on InvestorPlace.

Minerva Neurosciences News: NERV Stock Up on Insomnia Treatment Trial

Shares of thinly traded micro-cap biotech Minerva Neurosciences Inc spiked higher on Monday.

Minerva Spikes Higher After Novel Insomnia Drug Aces Mid-Stage Trial

Minerva Neurosciences Inc. (NASDAQ: NERV) saw its shares jump on Monday after the firm announced results from a trial related to an insomnia treatment.

How Minerva Neurosciences Is Outsmarting Insomia

Minerva Neurosciences Inc.  said Monday its trial of Seltorexant as a treatment for insomnia met its primary and key secondary goals.

Minerva Neurosciences says trial of insomnia treatment met primary and key secondary goals

Minerva Neurosciences released results from its phase 2b study using Seltorexant to treat patients with major depressive disorder.

Minerva Stock Drops On Initial Reaction To Data, But Multiple Catalysts Are On The Way

Shares of the microcap biotech Minerva Neurosciences Inc  were pulling back to their lowest level in a year Monday following the release of a clinical trial readout.

Minerva Neurosciences Sinks To Lowest Level In A Year On Cloudy Midstage Trial Results For Depression Drug

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q1 2019 Results - Earnings Call Transcript

NERV earnings call for the period ending December 31, 2018.

News for Minerva Neurosciences Stock (NERV)